



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



GPR52 Comp-43

Item No. 33564

CAS Registry No.: 1239987-91-7
Formal Name: (2E)-5-phenyl-1-(2-thienyl)-2-penten-1-one
Synonym: GPR52-IN-43
MF: C₁₅H₁₄OS
FW: 242.3
Purity: ≥98%
UV/Vis.: λ_{max}: 270 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GPR52 comp-43 is supplied as a crystalline solid. A stock solution may be made by dissolving the GPR52 comp-43 in the solvent of choice, which should be purged with an inert gas. GPR52 comp-43 is soluble in the organic solvent chloroform at a concentration of approximately 10 mg/ml.

Description

GPR52 comp-43 is an antagonist of G protein-coupled receptor 52 (GPR52; IC₅₀ = 0.63 μM).¹ It reduces mutant huntingtin (mHTT) protein levels in STHdh^{Q7/Q111} cells, a heterozygous *in vitro* model of Huntington's disease, in a concentration-dependent manner. GPR52 comp-43 (3 μM) reduces apoptosis induced by growth factor deprivation in primary striatal neurons isolated from the heterozygous Hdh^{Q7/Q140} mouse model of Huntington's disease. It decreases striatal levels of soluble and insoluble mHTT, as well as increases the latency to fall in the rotarod test, in the homozygous Hdh^{Q140} mouse model of Huntington's disease, when administered at a dose of 5 mg/kg.

Reference

1. Wang, C., Zhang, Y.-F., Guo, S., *et al.* GPR52 antagonist reduces huntingtin levels and ameliorates Huntington's disease-related phenotypes. *J. Med. Chem.* **64**(2), 941-957 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/27/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM